Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT04740034
What this trial is testing

AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 42
Early research (Phase 1)Ended earlyNCT04117958
What this trial is testing

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Who this might be right for
MUC17-positive Solid Tumors
Amgen 58
Early research (Phase 1)Looking for participantsNCT07581704
What this trial is testing

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Christopher Strouse 10
Testing effectiveness (Phase 2)Looking for participantsNCT06642792
What this trial is testing

AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin Lymphoma
Akeso 280
Early research (Phase 1)Study completedNCT05101109
What this trial is testing

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
ABL Bio, Inc. 24
Testing effectiveness (Phase 2)UnknownNCT05390528
What this trial is testing

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

Who this might be right for
Advanced TumorsLymphomaMetastatic Tumors
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)Study completedNCT04728321
What this trial is testing

Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Akeso 32
Testing effectiveness (Phase 2)Looking for participantsNCT07208773
What this trial is testing

YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsNon Small Cell Lung CancerSmall Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Testing effectiveness (Phase 2)Ended earlyNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 46
Early research (Phase 1)Looking for participantsNCT04903795
What this trial is testing

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

Who this might be right for
Newly Diagnosed GlioblastomaRecurrent Glioblastoma
Mustafa Khasraw, MBChB, MD, FRCP, FRACP 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557098
What this trial is testing

Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 194
Testing effectiveness (Phase 2)WithdrawnNCT03524274
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Who this might be right for
Advanced Colorectal Cancer
Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)UnknownNCT03879382
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

Who this might be right for
POMES SyndromeRelapsed and Refractory POMES Syndrome
Hrain Biotechnology Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT03038880
What this trial is testing

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Who this might be right for
Neovascularization, ChoroidalMacular Degeneration, Age-Related
Hoffmann-La Roche 76
Testing effectiveness (Phase 2)WithdrawnNCT01138579
What this trial is testing

Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation

Who this might be right for
LeukemiaStem Cell Transplantation
Technical University of Munich
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07648459
What this trial is testing

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07644208
What this trial is testing

PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT06712316
What this trial is testing

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 1,580
Testing effectiveness (Phase 2)WithdrawnNCT03540199
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Who this might be right for
Advanced Kidney Cancer
Fuda Cancer Hospital, Guangzhou
Next Page